|
SE9301916D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptides derivatives
|
|
ZA951617B
(en)
|
1994-03-04 |
1997-02-27 |
Lilly Co Eli |
Antithrombotic agents.
|
|
EP1082324A4
(en)
|
1998-05-26 |
2002-01-02 |
Merck & Co Inc |
IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
|
|
AU3192500A
(en)
|
1999-03-16 |
2000-10-04 |
C & C Research Laboratories |
Substituted proline derivatives and medicinal compositions containing the same
|
|
US7015230B1
(en)
|
1999-05-19 |
2006-03-21 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
|
|
US6653316B1
(en)
|
1999-05-19 |
2003-11-25 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
HUP0202191A3
(en)
|
1999-05-19 |
2003-02-28 |
Pharmacia Corp Chicago |
Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them
|
|
JP2004516286A
(ja)
|
2000-12-18 |
2004-06-03 |
メルク エンド カムパニー インコーポレーテッド |
ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用
|
|
CA2462647A1
(en)
|
2001-10-03 |
2003-04-10 |
Michael S. South |
6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
|
|
US20140056873A1
(en)
|
2004-06-10 |
2014-02-27 |
University Of Leicester |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
DE602006010834D1
(de)
*
|
2005-03-16 |
2010-01-14 |
Janssen Pharmaceutica Nv |
Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
|
|
AU2007342223B2
(en)
|
2007-01-10 |
2011-02-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
EP3150635A3
(en)
|
2009-10-16 |
2017-06-21 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
DK2694108T3
(en)
|
2011-04-08 |
2018-08-20 |
Univ Leicester |
METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
HUE049154T2
(hu)
|
2011-05-04 |
2020-09-28 |
Omeros Corp |
Készítmények a MASP-2-függõ komplement-aktiválás gátlására
|
|
PT2861246T
(pt)
|
2012-06-18 |
2021-04-05 |
Univ Leicester |
Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
|
|
AR091490A1
(es)
|
2012-06-19 |
2015-02-11 |
Bristol Myers Squibb Co |
Antagonistas de iap
|
|
EP2922535B1
(en)
|
2012-11-20 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
Thrombin inhibitors
|
|
RS61351B1
(sr)
|
2013-10-17 |
2021-02-26 |
Omeros Corp |
Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
|
|
CN117398458A
(zh)
|
2015-11-09 |
2024-01-16 |
奥默罗斯公司 |
用于治疗与masp-2依赖性补体活化相关的病况的方法
|
|
CA3010593C
(en)
|
2016-01-05 |
2024-02-13 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
US20170253667A1
(en)
|
2016-01-05 |
2017-09-07 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
NZ745531A
(en)
*
|
2016-03-31 |
2020-09-25 |
Omeros Corp |
Methods for inhibiting angiogenesis in a subject in need thereof
|
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
|
US20180105604A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
|
|
BR112020004800A2
(pt)
|
2017-09-13 |
2020-09-24 |
Amgen Inc. |
compostos de bisamida ativantes do sarcômero e seus usos
|
|
GB201805174D0
(en)
*
|
2018-03-29 |
2018-05-16 |
Univ Leeds Innovations Ltd |
Compounds
|
|
GB201807014D0
(en)
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
|
WO2019231935A1
(en)
|
2018-05-29 |
2019-12-05 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
AU2020395306B2
(en)
*
|
2019-12-04 |
2025-04-24 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
|
JP7699389B2
(ja)
*
|
2019-12-04 |
2025-06-27 |
オメロス コーポレーション |
Masp-2阻害剤および使用方法
|
|
BR112022010895A2
(pt)
|
2019-12-04 |
2022-09-06 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
|